MAPK8 and triple-negative breast carcinoma: The covalent JNK inhibitor JNK-IN-8 overcomes NRF2 activation caused by lapatinib treatment by inhibiting the JNK pathway, increasing ROS levels and promoting triple negative breast cancer cell apoptosis [84].